In the news release, 2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line...

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present multiple clinical study results of its novel Nectin-4-targeting...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology,...

The 53rd annual conference Art Gallery and Art Papers programs spotlight groundbreaking work at the intersection of digital art, research, interactive media, and emerging technologies. LOS...

- Data from novel Top1i ADC and T-cell engager platforms highlight potential within solid tumors and blood cancers, including oral presentations in prostate cancer, small cell lung cancer,...

M&T Bank Corporation ("M&T") (NYSE:MTB) will participate in the Morgan Stanley US Financials Conference being held in New York City. Representatives of M&T are scheduled to deliver a presentation...

Formosa Pharmaceuticals, Inc. announces that its abstract highlighting the differentiated binding profile and preclinical efficacy of TSY-310, a novel bispecific antibody-drug conjugate (ADC), has...

New data demonstrate the potential of the Canopy Remote Therapeutic Monitoring (RTM) Platform to improve patient care by reducing hospitalizations and increasing time on treatment. NEW YORK, May...

Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO® (pralsetinib) as first-line treatment in patients with RET...

Updated efficacy and safety data from a long-term analysis of the Phase 3 INDIGO trial of VORANIGO® (vorasidenib) will be presented in a rapid oral presentation Results from an ongoing Phase 1...